Hypertension, Cardiovascular diseases
Conditions
Interventions
Telmesartan group:telmesartan capsule 40mg/day
Beijing 0 group:Beijing 0 tablets 0.5#/qd
placebo group:placebo tablets 0.5#/qd
Indapamide group:Indapamide 1.5mg/capsule, once two days
Sponsors
Beijing Double-Crane Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
All
Age
45 Years to 79 Years
Inclusion criteria
Inclusion criteria: 1. Age: 50-79(f)/45-79(m); 2. Blood pressure: 130<=SBP<140mmHg and DBP<90mmHg or 85<=DBP<90mmHg and SBP<140mmHg; 3. At least one of other cardiovascular risk factors; 4. Informed consent obtained.
Exclusion criteria
Exclusion criteria: 1. Diabetes mellitus(FPG>=7.0mmol/L and/or OGTT 2hPG>=11.1mmol/L); 2. Hypertensive patients(SBP>=140 mmHg and/or DBP>=90 mmHg); 3. Patients participating any other studies within three months or concomitantly; 4. Presence of renal dysfunction, Cr >133 mmol/L, or BUN > 14.2mmol/L; 5. Presence of hepatic dysfunction (AST and/or ALT is 3 times higher than normal limit); 6. Serum k+5.6 mmol/L; 7. Hypersensitive to study agents; 8. Stroke or myocardial infarction within 6 months of the enrollment; 9. PTCA or CABG within 2 months prior to the study; 10. Presence of malignant tumors or other serious diseases; 11. Pregnant or lactating women; women in reproductive age not using recognized contraceptive methods; 12. Impossible for follow up; 13. Indications of hypotensive drugs; 14. Indications or contraindication of study drugs; 15. Unsuitable for the study judged by physician in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| combined cardiovascular events, new onset hypertention; | — |
Secondary
| Measure | Time frame |
|---|---|
| fatal and nonfatal stroke or MI, cardiovascular death; | — |
Countries
China
Contacts
Public ContactLisheng Liu
Outcome results
None listed